ramucirumab + gemcitabine + cisplatin

This combination consists of **ramucirumab**, **gemcitabine**, and **cisplatin** administered together as an experimental multi-agent chemotherapy regimen. Ramucirumab is a recombinant human IgG1 monoclonal antibody that specifically binds to the extracellular domain of **vascular endothelial growth factor receptor 2 (VEGFR2)**, blocking the binding of ligands and thus inhibiting angiogenesis. Gemcitabine is a nucleoside analog (antimetabolite) that is incorporated into DNA, causing cell death during DNA replication. Cisplatin is a platinum-based compound that forms cross-links with DNA, inhibiting DNA synthesis and function, leading to apoptosis. This regimen has been tested in clinical trials primarily for locally advanced or metastatic **biliary tract cancer** but is not standard or approved therapy for this indication. It has also been investigated in other cancers but remains investigational.

Brand names

Cyramza (ramucirumab)

Other names

ramucirumab and cisplatin and gemcitabine